The dosage, safety, and efficacy of medical marijuana in treating the symptoms of cancer in children, are not well established.
Cannabis products have gained popularity among patients and families for managing cancer symptoms such as pain, anxiety, and weight loss (1✔ ✔Trusted Source
Cannabis and Cannabinoids (PDQ®)-Health Professional Version
Go to source). According to a recent study, there is insufficient data to establish the dosage, safety, and //effectiveness of medical marijuana in treating the symptoms of cancer in children. The analysis was published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society.
Evaluating Cannabis Effectiveness against Cancer Symptoms in Children
Although treatments for childhood cancer have improved significantly, even leading to cures for many patients, many children still suffer from symptoms related to cancer and its treatment.‘Researchers should develop standards for reporting cannabis exposures, cannabis‐related effects, and patient outcomes in cancer-affected children. #cannabisforcancer #kidshealth’
Over the last decade, cannabis products—both synthetic cannabinoids and natural phytocannabinoids—have gained popularity with patients and families for managing such symptoms, but pediatric oncologists are cautious to authorize cannabis for their patients given the limited data to inform dosing, product selection, and safety monitoring (2✔ ✔Trusted SourceSystematic review and meta-analysis of cannabinoids in palliative medicine
Go to source).
To provide insights for clinicians and parents, and to inform an upcoming clinical trial, a team led by Lauren E. Kelly, PhD, associate professor of pharmacology and therapeutics in the Rady Faculty of Health Sciences at the University of Manitoba, searched the medical literature to summarize existing knowledge about the potential benefits and harms of cannabis products in children with cancer.
Digging Deep in Clinical Trials to Test Cannabis Potency in Alleviating Cancer Symptoms
The investigators identified 19 unique studies with a total of 1,927 participants with cancer: eight retrospective chart reviews, seven randomized controlled trials, two open‐label studies, and two case reports. The products studied included medical-grade cannabinoids (such as the prescription drug nabilone), synthetic cannabinoids, and unspecified cannabis herbal extracts. Products were most commonly used to manage chemotherapy‐induced nausea and vomiting.In the randomized controlled trials, patients who used cannabinoids were more likely to experience drowsiness, feeling high, dizziness, and dry mouth. Also, trial participants who received cannabinoids were almost four times more likely to drop from the study due to adverse events, compared with the control group who received placebo. Across all included studies, no serious cannabis‐related adverse events were reported.
Dr. Kelly and her colleagues noted that most studies did not adequately describe the types, dosing, frequencies, and routes of administration of cannabis products, and outcomes were mixed and reported in different ways.
“It was difficult to measure benefit across studies, given a range of different outcomes and study designs; however, in interventional studies with active control groups, cannabinoids performed better in managing nausea and vomiting. Data are lacking on cannabinoids’ effects on pain, mood, sleep, and health-related quality of life,” said Dr. Kelly.
Advertisement
Reference:
- Cannabis and Cannabinoids (PDQ®)–Health Professional Version - (https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq)
- Systematic review and meta‐analysis of cannabinoids in palliative medicine- (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5879974/)